Read is betting his less-is-more strategy will yield better returns. So research programs in gene therapy and respiratory disease are gone. Pfizer’s animal health and infant nutrition businesses are being divested. And overlap from the $64 billion acquisition of Wyeth in 2009 is being cut. When Read is done transforming the world’s largest drugmaker, with 2011 sales of $67.4 billion, it will focus on cardiovascular diseases; cancer; neuroscience; vaccines; and inflammation and immunology.
If it is Pfizer: We all better hope that Pfizer becomes a partner and not the owner of PPHM. If owner, we are going to miss on a lot of splits and for some of us big share holders millions of dollars.
News 
Market Data 
Discover 
